Oxford Cancer Biomarkers

About:

Oxford Cancer is developing and commercialising a suite of colorectal cancer biomarker tests to improve the current treatment pathway.

Website: http://www.oxfordbio.com/

Top Investors: NHS England, Longwall Venture, Esperante Ventures, Kwang Dong Pharmaceutical

Description:

Oxford Cancer Biomarkers is developing and commercializing a suite of colorectal cancer biomarker tests to improve the current treatment pathway. Oxford Cancer Biomarkers is closely affiliated with Institute of Cancer Medicine at Oxford University, where its founders lead translational cancer science research groups. Oxford Cancer Biomarkers has also partnered with pharmaceutical companies to use its discovery platforms CancerNav® and ToxNavTM to develop companion diagnostic tests for pipeline drugs.